PARP inhibitors for prostate cancer: for whom and when?
Lancet Oncol
.
2025 Apr;26(4):404-406.
doi: 10.1016/S1470-2045(25)00125-1.
Author
Matthew R Cooperberg
1
Affiliation
1
Departments of Urology and Epidemiology and Biostatistics, University of California, San Francisco, CA 94143, USA. Electronic address: matthew.cooperberg@ucsf.edu.
PMID:
40179902
DOI:
10.1016/S1470-2045(25)00125-1
No abstract available